Children’s Hospital Los Angeles has expanded its cell and gene therapy program to include 12 FDA-approved therapies.
The program now offers more cell and gene therapies than any pediatric center on the West Coast, according to a March 5 news release from the hospital.
The therapies treat neuromuscular disorders, blood disorders, cancer, inherited retinal disease, dermatologic and transplantation-associated conditions.
The hospital plans to launch a clinical trial to study a sickle cell gene therapy product, as well as a CAR T-cell therapy developed by investigators at Children’s Hospital Los Angeles for pediatric solid tumors, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.